Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CRP1 CRISPR/Cas9 KO Plasmid (h): sc-406188
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CRP1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CRP1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CRP1 Antibody (F-12): sc-390418
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CRP1 CRISPR/Cas9 KO Plasmid (h) | sc-406188 | 20 µg | $397.00 |
Overview
CSRP1 encodes cysteine and glycine-rich protein 1 (CRP1), a LIM domain–containing actin-binding factor that modulates cytoskeletal organization and transcriptional programs linked to cell shape and motility. CRP1 participates in actin stress fiber dynamics and focal adhesion–associated signaling, helping coordinate smooth muscle differentiation and broader mesenchymal cell behavior. By influencing adhesion-dependent pathways and gene regulatory networks, CSRP1 is frequently studied in contexts of tissue remodeling and cellular invasion. Altered CSRP1 expression has been reported across multiple disease settings, including cancers and fibrotic pathologies, where changes in cytoskeletal control and differentiation state are central experimental themes.
CRP1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CSRP1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CSRP1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CSRP1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CRP1 protein expression.
This CRISPR knockout system enables efficient generation of CSRP1-deficient cell models for investigation of CRP1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CSRP1 exon(s) critical for CRP1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CSRP1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CRP1 CRISPR/Cas9 KO Plasmid (h) and CRP1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CSRP1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CRP1 HDR Plasmid (h) and CRP1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CSRP1 homology arms to support homology-directed repair at defined CSRP1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.